10 Micro-Cap Healthcare Stocks Insiders Are Buying

Yahoo FinanceApr 15 03:00

Buy Rating Affirmed for Palatin Technologies Following Successful Phase 3 Trial of PL9643 for Dry Eye Disease

TipRanksApr 8 23:05

Palatin Technologies Shares Rise 27% After Positive Trial Results for PL9643

By Chris Wack Palatin Technologies shares were up 27% to $2.24 after the company said it saw positive topline results for its Phase 3 pivotal clinical trial evaluating the safety and efficacy of PL96

WSJApr 8 22:46

Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data

On Monday, Palatin Technologies Inc. (NYSE:PTN) announced the presentation of topline results for its Phase 3 PL9643 MELODY-1 trial, which evaluated the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED) at the American Society of Cataract and Refractive Surgery.

BenzingaApr 8 22:02

Palatin Stock Jumps 16% on Positive Phase 3 Data for Eye Drug

Seeking AlphaApr 8 21:49

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024

Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announce

BenzingaApr 8 19:31